First, rofecoxib (Vioxx), a cyclooxygenase-2 inhibitor, was withdrawn from the market because of an adverse cardiovascular safety profile missed during its development.21,22 Then, the diabetes drug rosiglitazone (Avandia) was suspected of raising the risk of myocardial infarction, which also was not detected during its development.23 Finally, the ILLUMINATE trial results were even more concerning: There was a clear adverse effect of torcetrapib on cardiovascular and all-cause mortality outcomes despite a remarkable improvement in lipid profile.1 This evidence concerns the gene PTGS2 and diabetes mellitus.